Status:
COMPLETED
The Incorporation of Dietary Protein-Derived Amino Acids in Duodenal Epithelium
Lead Sponsor:
Maastricht University Medical Center
Collaborating Sponsors:
FrieslandCampina
Conditions:
Protein Malabsorption
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
Rationale: Aging is accompanied by a blunted muscle protein synthetic response to protein ingestion.This anabolic resistance may be related to decreased postprandial amino acid release in the circulat...
Detailed Description
Skeletal muscle tissue is in a constant state of remodelling, regulated by the balance between tissue protein synthesis and breakdown rates, with a turnover rate of 1-2% per day. It has been well esta...
Eligibility Criteria
Inclusion
- Male sex
- Aged 18-35 years or 67+ years
- Body mass index (BMI) between 18.5 and 30 kg/m2
Exclusion
- History of cardiovascular, respiratory, gastrointestinal, urogenital, neurological, psychiatric, dermatologic, musculoskeletal, metabolic, endocrine, haematological, immunologic disorders, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol, interfere with the execution of the experiment, or potential influence the study outcomes (to be decided by the principal investigator and responsible physician)
- Major abdominal surgery interfering with gastrointestinal function (upon judgement of the principal investigator and responsible physician)
- Use of medication which limit participation in or completion of the study protocol, interferes with the execution of the experiment, or potential influences the study outcomes (to be decided by the principal investigator and responsible physician)
- Use of supplementation (i.e. vitamin, pre- and probiotic supplementation) within 14 days prior to testing
- Administration of investigational drugs or participation in any scientific intervention study in the 14 days prior to the study, which may interfere with this study (upon judgement of the principal investigator and responsible physician)
- Specific diet (e.g. vegetarian, vegan, gluten free, no diary) within the study period
- Planning to lose weight during the study period
- Lactose intolerance
- Excessive alcohol consumption (defined as \> 14 alcoholic consumptions per week)
- Smoking
- Drug use
- Donated blood two months prior to the test day
- Recent (\<1 year) participation in amino acid tracer (L-\[ring-2H5\]-phenylalanine, L-\[ring-2H3\]-leucine, L-\[ring-2H4\]-lysine, L-\[ring-2H2\]-tyrosine) or intrinsically labelled protein (\[1-13C\]-phenylalanine, \[1-13C\]-leucine, \[1-13C\]-lysine) studies
- No given permission to register participation in electronic patient file at MUMC+ and to add records of gastroduodenoscopy
Key Trial Info
Start Date :
July 24 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 5 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06091852
Start Date
July 24 2023
End Date
April 5 2024
Last Update
April 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht University Medical Center+
Maastricht, Netherlands, 6229ER